Cost comparison analysis: Pentaerythrithyl tetranitrate (PETN) and isosorbide dinitrate (ISDN) prescribed to diabetic patients in primary care practices in Germany

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 9, 2007, Pages 516-523

  Icks, A ^a   Haastert, B ^a   Rathmann, W ^a   Schroder Bemhardi D ^b   Giani, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b IQVIA   (United States)

Author keywords

Cardiovascular disease; Cost comparison analysis; Diabetes; Prescription patterns; Primary care

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIURETIC AGENT; GLYCOSIDE; INSULIN; ISOSORBIDE DINITRATE; MOLSIDOMINE; NITRIC ACID DERIVATIVE; PENTAERYTHRITYL TETRANITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG COST; FEMALE; GERMANY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIMARY MEDICAL CARE;

EID: 34548641484     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45516     Document Type: Article

References (11)

1. Barber JA, Thompson SG. Analysis and interpretation of cost data in randomized controlled trials: review of published studies. BMJ. 1998; 317: 1195-2000.
2. Dietlein G, Schröbder-Bernhardi D. Use of the mediplus patient database in health care research. Int J Clin Pharmacol Therap. 2002; 40: 130-133.
3. Federal Statistic Office (eds). Health Report for Germany. Stuttgart, Metzler-Poeschel, 1998.
4. Gori T, Burstein JM, Ahmed S et al. Comparison of the effects of pentaerythritol tetranitrate and nitroglycerine dependent vasorelaxation in male volunteers. Am J Cardiology. 2003; 91: 1392-1394.
5. Häussler B, Bentz J, Nolting HD. Arzneimittelverbrauch und Morbiditätsuntersehiede. In: Laukant A (ed). Arzneimittelverbrauch in Ost- und Westdeutschland. Mürnberg: Novartis Pharma; 1998.
6. Jurt U, Gori T Ravandi A, Babae I, Zeman P, Parker JD. Differential effects of pentaerythritol tetranitrate and nitroglycerine on the development of tolerance and evidence of lipid oxidation: a human in vivo study. J Am Coll Cardiol. 2001; 38: 854-859.
7. Keimer R, Stutzer FK, Tsikas D, Troost R, Gutzki FM, Fröhlich JC. Lack of oxidative stress during sustained therapy with isosorbide dinitrate and pentaerythritol tetranitrate in healthy humans: a randomized, double-blind and crossover study. J Cardiovasc Pharmacol. 2003; 41: 284-292.
8. Müller-Nordhorn J, Kulig M, Binting S, Völler H, Krobot KJ, Willich S. Regional variation in medication following coronary events in Germany. Int J Cardiol. 2005; 102: 47-53.
9. Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA et al. Endothelial protection by pentaerythritol tetranitrate: Bilirubin and carbon monoxide as possible mediators. Exp Biol Med. 2003; 228: 529-534.
10. Rathmann W, Haastert B, Roseman JM, Gries FA, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care. 1998; 21: 389-397.
11. Zeiher AM, Dabrowski M, Lehmacher W. Das Langzeitnitrat PETN ist ISDN-SR nicht unterlegen und zeigt therapeutische Vorteile in der Langzeitbehandlung der stabilen Angina pectoris. Z Kardiol. 2004; 93 (Sappl 5): 112.